Towards an epidemiology of the known unknowns in cryptogenic stroke

Heart

Volumn 98, Issue 15, 2012, Pages 1114-1116

  Dahabreh, Issa J ^a   Kent, David M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; EDITORIAL; HEART LEFT RIGHT SHUNT; HUMAN; PATENT FORAMEN OVALE; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; VENOUS THROMBOEMBOLISM;

HUMANS; MORBIDITY; RISK FACTORS; STROKE; WORLD HEALTH; YOUNG ADULT;

EID: 84863803711     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301648     Document Type: Editorial

References (14)

1. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
2. Pezzini A, Grassi M, Lodigiani C, et al. Interaction between proatherosclerotic factors and right-to-left shunt on the risk of cryptogenic stroke: the Italian Project on Stroke in Young Adults. Heart 2012;98:485-9.
3. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of casecontrol studies. Neurology 2000;55:1172-9.
4. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke 2009;40:2349-55.
5. Di Tullio M, Sacco RL, Gopal A, et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992;117:461-5.
6. Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002;33:706-11.
7. Rodes-Cabau J, Noel M, Marrero A, et al. Atherosclerotic burden findings in young cryptogenic stroke patients with and without a patent foramen ovale. Stroke 2009;40:419-25.
8. Kent DM, Thaler DE. Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke 2010;41:S26-30.
9. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 2011;305:822-3.
10. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15:615-25.
11. Department of Defense. News Briefing - Secretary Rumsfeld and Gen. Myers; News Transcript. U.S. Department of Defense, Office of the Assistant Secretary of Defense (Public Affairs), 2002. http://www.defense.gov/transcripts/ transcript.aspx?transcriptid=2636
12. Taubman SL, Robins JM, Mittleman MA, et al. Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol 2009;38:1599-611.
13. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, et al. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012;43:422-31.
14. Kent DM, Thaler DE. The Risk of Paradoxical Embolism (RoPE) Study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. Trials 2011;12:185.